DE60126483D1 - Gezielten modifikation der chromatinstruktur - Google Patents

Gezielten modifikation der chromatinstruktur

Info

Publication number
DE60126483D1
DE60126483D1 DE60126483T DE60126483T DE60126483D1 DE 60126483 D1 DE60126483 D1 DE 60126483D1 DE 60126483 T DE60126483 T DE 60126483T DE 60126483 T DE60126483 T DE 60126483T DE 60126483 D1 DE60126483 D1 DE 60126483D1
Authority
DE
Germany
Prior art keywords
targeted modification
chromatin structure
compositions
methods
chromatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60126483T
Other languages
English (en)
Other versions
DE60126483T2 (de
Inventor
P Wolffe
Trevor Collingwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangamo Therapeutics Inc
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Application granted granted Critical
Publication of DE60126483D1 publication Critical patent/DE60126483D1/de
Publication of DE60126483T2 publication Critical patent/DE60126483T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ecology (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
DE60126483T 2000-04-28 2001-04-27 Gezielte Modifikation der Chromatinstruktur Expired - Lifetime DE60126483T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20059000P 2000-04-28 2000-04-28
US200590P 2000-04-28
US22852300P 2000-08-28 2000-08-28
US228523P 2000-08-28
PCT/US2001/040616 WO2001083793A2 (en) 2000-04-28 2001-04-27 Targeted modification of chromatin structure

Publications (2)

Publication Number Publication Date
DE60126483D1 true DE60126483D1 (de) 2007-03-22
DE60126483T2 DE60126483T2 (de) 2007-12-06

Family

ID=26895902

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60126483T Expired - Lifetime DE60126483T2 (de) 2000-04-28 2001-04-27 Gezielte Modifikation der Chromatinstruktur

Country Status (7)

Country Link
US (4) US7001768B2 (de)
EP (1) EP1276859B1 (de)
AT (1) ATE353361T1 (de)
AU (2) AU2001253914B2 (de)
CA (1) CA2407460C (de)
DE (1) DE60126483T2 (de)
WO (1) WO2001083793A2 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
DE60128122D1 (de) * 2000-09-28 2007-06-06 Sangamo Biosciences Inc Kernumprogrammierung bei iswi und ähnlichen chromatinremodellierenden atpasen
WO2002026960A2 (en) * 2000-09-29 2002-04-04 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
US6919204B2 (en) * 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
US7026462B2 (en) * 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US6989245B2 (en) * 2001-05-11 2006-01-24 The Burnham Institute Screening, diagnostic and therapeutic methods relating to RIZ
EP1402053A4 (de) * 2001-06-05 2005-05-11 Exelixis Inc Chds als modifikatoren des p53-wegs und verwendungsverfahren
US7264964B2 (en) * 2001-06-22 2007-09-04 Ceres, Inc. Chimeric histone acetyltransferase polypeptides
GB0117964D0 (en) * 2001-07-24 2001-09-19 Imp College Innovations Ltd Control of gene expression
CA2461290C (en) 2001-09-24 2014-11-25 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
CA2488697C (en) 2002-06-06 2010-05-25 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Regulation of gene expression using chromatin remodelling factors
US7553667B2 (en) 2002-06-06 2009-06-30 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Regulation of gene expression using chromatin remodelling factors
EP1579005A4 (de) * 2002-11-15 2007-07-25 Sangamo Biosciences Inc Verfahren und zusammensetzungen zur analyse regulatorischer sequenzen
EP1570061A2 (de) * 2002-12-05 2005-09-07 Imperial College Innovations Limited Kontrolle der apoptosis durch verwendung eines komplexes aus einem oligonucleotid und einem regulatorischen peptid
WO2004085644A2 (en) * 2003-03-26 2004-10-07 Basf Plant Science Gmbh Method for producing recombinant organisms
CA2534296C (en) 2003-08-08 2013-03-26 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ATE518960T1 (de) 2003-09-19 2011-08-15 Sangamo Biosciences Inc Gentechnisch hergestellte zinkfingerproteine zur regulation der genexpression
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) * 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) * 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
JP4838722B2 (ja) 2003-10-24 2011-12-14 ゲンシア コーポレーション ポリヌクレオチドを送達する方法、及び送達用組成物
US7855824B2 (en) * 2004-03-06 2010-12-21 Qualcomm Mems Technologies, Inc. Method and system for color optimization in a display
US20060063231A1 (en) * 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
US7358085B2 (en) 2005-02-28 2008-04-15 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
US8999943B2 (en) 2005-03-14 2015-04-07 Board Of Regents, The University Of Texas System Antigene oligomers inhibit transcription
EP2641970B1 (de) 2005-11-17 2014-12-24 Board of Regents, The University of Texas System Modulierung der Genexpression durch Oligomere, die auf chromosomale DNA ausgerichtet sind
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
GB0607063D0 (en) 2006-04-07 2006-05-17 Cellcentric Ltd Compositions and methods for epigenetic modification of nucleic acid sequences in vivo
EP2049663B1 (de) 2006-08-11 2015-02-25 Dow AgroSciences LLC Zinkfingernuklease-vermittelte homologe rekombination
AU2007334468B2 (en) 2006-12-14 2013-02-07 Corteva Agriscience Llc Optimized non-canonical zinc finger proteins
CN101878307B (zh) * 2007-09-27 2017-07-28 陶氏益农公司 以5‑烯醇式丙酮酰莽草酸‑3‑磷酸合酶基因为靶的改造锌指蛋白
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2232569A2 (de) 2007-12-17 2010-09-29 QUALCOMM MEMS Technologies, Inc. PHOTOVOLTAIsche Elemente mit INTERFEROMETRIschen Rückseitenmasken
AU2008343193B2 (en) * 2007-12-20 2014-04-24 Ethicon, Incorporated Encapsulated kidney tissue
US8222221B2 (en) 2008-06-04 2012-07-17 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small RNA targeting of gene promoters
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2206723A1 (de) 2009-01-12 2010-07-14 Bonas, Ulla Modulare DNA-bindende Domänen
AU2010211057B2 (en) * 2009-02-04 2014-12-18 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathies
US8871905B2 (en) 2009-03-20 2014-10-28 Sangamo Biosciences, Inc. Modification of CXCR4 using engineered zinc finger proteins
EP2421972A2 (de) 2009-04-24 2012-02-29 The Board of Regents of The University of Texas System Modulation der genexpression mit auf genregionen nach 3-untranslatierten regionen gerichteten oligomeren
AU2010281705B2 (en) 2009-07-28 2015-02-05 Sangamo Therapeutics, Inc. Methods and compositions for treating trinucleotide repeat disorders
EP2491127B1 (de) 2009-10-22 2017-09-20 Dow AgroSciences LLC Manipulierte zinkfingerproteine zur abzielung auf in fettsäure-biosynthese involvierte pflanzengene
US8586363B2 (en) 2009-12-10 2013-11-19 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
EP3156062A1 (de) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Neuartige dna-bindende proteine und verwendungen davon
CN103354715A (zh) 2011-01-14 2013-10-16 双刃基金会 具有针对柑橘溃疡病的抗性的柑橘树
CA2844470A1 (en) * 2011-06-21 2013-05-10 Pioneer Hi-Bred International, Inc. Methods and compositions for producing male sterile plants
AR087167A1 (es) 2011-07-12 2014-02-26 Two Blades Foundation Genes de resistencia al tizon tardio
EP3461896B1 (de) 2011-07-15 2023-11-29 The General Hospital Corporation Verfahren zur transkription einer aktivatorähnlichen effektoranordnung
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US10801017B2 (en) * 2011-11-30 2020-10-13 The Broad Institute, Inc. Nucleotide-specific recognition sequences for designer TAL effectors
BR112014018294B1 (pt) 2012-01-26 2022-01-11 Norfolk Plant Sciences, Ltd Método para produzir uma planta, cassete de expressão, e, célula bacteriana
WO2013119705A2 (en) * 2012-02-06 2013-08-15 University Of Iowa Research Foundation Method of regulating cftr expression and processing
US10570378B2 (en) 2012-02-28 2020-02-25 Sigma-Aldrich Co. Llc Targeted histone acetylation
AU2013225950B2 (en) 2012-02-29 2018-02-15 Sangamo Therapeutics, Inc. Methods and compositions for treating huntington's disease
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
US9815877B2 (en) 2012-06-07 2017-11-14 The Children's Hospital Of Philadelphia Controlled gene expression methods
BR112014031891A2 (pt) 2012-06-19 2017-08-01 Univ Minnesota direcionamento genético nas plantas utilizando vírus de dna
EP3763810A3 (de) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T-zell-modifizierende verbindungen und verwendungen davon
US20150267176A1 (en) * 2012-10-12 2015-09-24 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
BR112015009967B1 (pt) 2012-11-01 2022-07-12 Medicago Inc. Método para a produção de um polipeptídeo terapêutico
US10415024B2 (en) 2012-11-16 2019-09-17 Poseida Therapeutics, Inc. Site-specific enzymes and methods of use
ES2673864T3 (es) 2012-12-21 2018-06-26 Cellectis Patatas con endulzamiento inducido en frío reducido
EP3623463B1 (de) 2013-02-07 2021-10-20 The General Hospital Corporation Tale-transkriptionsaktivatoren
IL289396B2 (en) 2013-03-15 2023-12-01 The General Hospital Coporation Using tru-grnas to increase the specificity of RNA-guided genome editing
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10113162B2 (en) 2013-03-15 2018-10-30 Cellectis Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
US9828582B2 (en) * 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
CA2930015A1 (en) 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
CN105934524A (zh) 2013-11-11 2016-09-07 桑格摩生物科学股份有限公司 用于治疗亨廷顿氏病的方法和组合物
WO2015116680A1 (en) 2014-01-30 2015-08-06 Two Blades Foundation Plants with enhanced resistance to phytophthora
CA2942762C (en) 2014-03-18 2023-10-17 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
US9522936B2 (en) 2014-04-24 2016-12-20 Sangamo Biosciences, Inc. Engineered transcription activator like effector (TALE) proteins
WO2015171603A1 (en) 2014-05-06 2015-11-12 Two Blades Foundation Methods for producing plants with enhanced resistance to oomycete pathogens
WO2015193858A1 (en) 2014-06-20 2015-12-23 Cellectis Potatoes with reduced granule-bound starch synthase
WO2016089920A1 (en) 2014-12-01 2016-06-09 The Broad Institute, Inc. Method for in situ determination of nucleic acid proximity
WO2016182881A1 (en) 2015-05-09 2016-11-17 Two Blades Foundation Late blight resistance gene from solanum americanum and methods of use
JP2018521689A (ja) 2015-06-17 2018-08-09 ポセイダ セラピューティクス， インコーポレイテッド タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US10837024B2 (en) 2015-09-17 2020-11-17 Cellectis Modifying messenger RNA stability in plant transformations
WO2017062790A1 (en) 2015-10-09 2017-04-13 Two Blades Foundation Cold shock protein receptors and methods of use
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
JP2018537112A (ja) 2015-12-18 2018-12-20 サンガモ セラピューティクス， インコーポレイテッド Ｍｈｃ細胞受容体の標的化破壊
EP3389677B1 (de) 2015-12-18 2024-06-26 Sangamo Therapeutics, Inc. Gezielte zerstörung des t-zell-rezeptors
UY37108A (es) 2016-02-02 2017-08-31 Cellectis Modificación de la composición de aceites de soja mediante el knockout dirigido de los genes fad3a/b/c
KR20220145913A (ko) 2016-08-24 2022-10-31 상가모 테라퓨틱스, 인코포레이티드 가공된 표적 특이적 뉴클레아제
US10960085B2 (en) 2016-09-07 2021-03-30 Sangamo Therapeutics, Inc. Modulation of liver genes
WO2018092072A1 (en) 2016-11-16 2018-05-24 Cellectis Methods for altering amino acid content in plants through frameshift mutations
WO2018112356A1 (en) 2016-12-16 2018-06-21 Two Blades Foundation Late blight resistance genes and methods of use
ES2977620T3 (es) 2017-04-25 2024-08-27 Cellectis Alfalfa con composición reducida de lignina
IL301115A (en) 2017-04-28 2023-05-01 Acuitas Therapeutics Inc New lipid carbonyl and lipid nanoparticle formulations for delivery of nucleic acids
WO2018204469A2 (en) 2017-05-03 2018-11-08 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
WO2018209209A1 (en) 2017-05-12 2018-11-15 Two Blades Foundation Methods for screening proteins for pattern recognition receptor function in plant protoplasts
US11261458B2 (en) 2017-07-28 2022-03-01 Two Blades Foundation Potyvirus resistance genes and methods of use
WO2019108619A1 (en) 2017-11-28 2019-06-06 Two Blades Foundation Methods and compositions for enhancing the disease resistance of plants
MA50942A (fr) 2017-12-01 2020-10-07 Encoded Therapeutics Inc Protéines de liaison à l'adn modifiées
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
EP3737226A1 (de) 2018-01-12 2020-11-18 Two Blades Foundation Stammrostresistenzgene und verfahren zur verwendung
US11421007B2 (en) 2018-04-18 2022-08-23 Sangamo Therapeutics, Inc. Zinc finger protein compositions for modulation of huntingtin (Htt)
JP7555822B2 (ja) 2018-04-19 2024-09-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア ゲノム編集のための組成物および方法
AU2019326408A1 (en) 2018-08-23 2021-03-11 Sangamo Therapeutics, Inc. Engineered target specific base editors
EP3853244A4 (de) 2018-09-18 2022-09-14 Sangamo Therapeutics, Inc. Für programmierten zelltod 1 (pd1) spezifische nukleasen
JP7523449B2 (ja) 2019-01-11 2024-07-26 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
BR112021026248A2 (pt) 2019-06-27 2022-03-03 Two Blades Found Molécula de ácido nucleico isolada que codifica uma proteína atrlp23 engenheirada, proteína atrlp23 engenheirada, cassete de expressão, vetor, célula hospedeira, planta ou célula vegetal, métodos para fazer uma proteína atrlp23 engenheirada, para fazer uma molécula de ácido nucleico que codifica uma proteína atrlp23 engenheirada e para intensificar a resistência de uma planta
US20210071193A1 (en) 2019-07-12 2021-03-11 The Regents Of The University Of California Plants with enhanced resistance to bacterial pathogens
AU2021308681A1 (en) 2020-07-16 2023-03-09 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
EP4204545A2 (de) 2020-08-25 2023-07-05 Kite Pharma, Inc. T-zellen mit verbesserter funktionalität
US20240218356A1 (en) 2021-05-11 2024-07-04 Two Blades Foundation Methods for preparing a library of plant disease resistance genes for functional testing for disease resistance
CA3233676A1 (en) 2021-09-30 2023-04-06 The Sainsbury Laboratory Plant disease resistance genes against stem rust and methods of use
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023250511A2 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
WO1997011972A1 (en) * 1995-09-28 1997-04-03 The Trustees Of Columbia University In The City Of New York Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
JP2850816B2 (ja) * 1995-12-18 1999-01-27 日本電気株式会社 バンプ接合検査装置及び検査方法
US6015709A (en) * 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5972608A (en) * 1997-08-27 1999-10-26 University Of Massachusetts Assays and reagents for chromatin remodeling enzymes and their modulators
US6153383A (en) * 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
WO1999045132A1 (en) * 1998-03-02 1999-09-10 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US20020188103A1 (en) * 1998-10-09 2002-12-12 Timothy H. Bestor Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
WO2001052620A2 (en) * 2000-01-21 2001-07-26 The Scripps Research Institute Methods and compositions to modulate expression in plants
WO2001059450A2 (en) * 2000-02-08 2001-08-16 Sangamo Biosciences, Inc. Cells expressing zinc finger protein for drug discovery
AU2001236961A1 (en) 2000-02-11 2001-08-20 The Salk Institute For Biological Studies Method of regulating transcription in a cell by altering remodeling of cromatin
WO2001068807A2 (en) * 2000-03-16 2001-09-20 Fred Hutchinson Cancer Research Center Identification of in vivo dna binding loci of chromatin proteins using a tethered nucleotide modification enzyme

Also Published As

Publication number Publication date
US20060188972A1 (en) 2006-08-24
CA2407460C (en) 2013-06-25
WO2001083793A2 (en) 2001-11-08
US20090023153A1 (en) 2009-01-22
DE60126483T2 (de) 2007-12-06
WO2001083793A3 (en) 2002-06-20
EP1276859B1 (de) 2007-02-07
US7785792B2 (en) 2010-08-31
AU5391401A (en) 2001-11-12
AU2001253914B2 (en) 2006-06-08
US7001768B2 (en) 2006-02-21
US8071370B2 (en) 2011-12-06
US20020115215A1 (en) 2002-08-22
US20100323424A1 (en) 2010-12-23
ATE353361T1 (de) 2007-02-15
EP1276859A2 (de) 2003-01-22
CA2407460A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
DE60126483D1 (de) Gezielten modifikation der chromatinstruktur
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
ATE296094T1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
CY1117027T1 (el) Συνεργιστικοι μυκητοκτονοι συνδυασμοι δραστικων ουσιων
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
WO2004062613A3 (en) Hiv integrase inhibitors
RS20050769A (en) Derivatives of 2-acylamino-4- phenylthiazole,preparation method thereof and application of same in therapeutics
DE69837393D1 (de) Stimulierung von hämatopoietischen zellen im vitro
CY1108549T1 (el) Συνθετικες μεθοδοι για απλιδινη και νεα κατα του ογκου παραγωγα, μεθοδοι κατασκευης και χρησης αυτων
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
AR030961A1 (es) Secuencias de nucleotidos que intervienen en la fertilidad masculina en plantas y metodo de uso de las mismas
NO20062978L (no) Reduksjon av dermal arrdannelse
MXPA02012042A (es) Compuestos efectivos como agonistas de beta-2-adrenorreceptor, y como inhibidores de pde4.
UY25712A1 (es) Benzamidas sustituidas y su aplicación en medicamentos
MXPA06002349A (es) Derivados de aminopropanol.
MXPA05002489A (es) Composiciones para el cuidado personal basadas en alcohol ramificado.
TR201820474T4 (tr) Spesifik immün modülatör profilleri indükleyen tanımlı nükleotitler arası bağlar bağlamında rna sekansı motifleri.
RS20070095A (en) Alkyliden-tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents
DE602004028493D1 (de) Isochinolinon-kaliumkanalinhibitoren
BRPI0500773A (pt) método para secagem de neotame com um co-agente para proporcionar um produto sólido contendo neotame, e, produto sólido contendo neotame possuindo uniformidade melhorada e estabilidade melhorada
RS20060206A (en) Aminopyridine-derivatives as inducible no-synthase inhibitors
EA200401032A1 (ru) Антиинфарктные молекулы
BR0114884A (pt) Compostos calcilìticos
ATE409191T1 (de) 1,3-diaza-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
BR0106265B1 (pt) processo para cultura aeràbica.

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: WOLFFE, ALAN P., ORINDA, CALIF., US

Inventor name: COLLINGWOOD, TREVOR, SAN PABLO, CALIF., US

8364 No opposition during term of opposition